Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in this blog.

There appears to be updated data on Entrectinib (RXDX-101) and TSR -011. Specifically for RXDX-101, 67  patients have been tested, and among 17 inhibitor (not just ALK) naive patients (10/11) 91% treated at or above 400 mg/m2 achieved an objective response rate with durable responses up to 16 cycles (a cycle appears to be 4 weeks so that would be a durable response up to 64 weeks).

Specifically for TSR-011, 69 patients were tested and 46 ALK+ NSCLC patients were reported. For total daily doses at or above 120 mg, 3/5 (60%) ALK inhibitor naive patients responded and 3/6 (50%) patients who had progressed on Crizotinib responded. Unclear if a “response” is an objective response only or includes stable responses.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699265/

This entry was posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply